Screening of brain metastasis with limited magnetic resonance imaging (MRI): clinical implications of using limited brain MRI during initial staging for non-small cell lung cancer patients.
The purpose of this prospective study was to determine whether using magnetic resonance imaging (MRI) for early screening for brain metastases (BM) can improve quality of life, survival in patients with non-small cell lung cancer (NSCLC). The study group comprised 183 patients newly diagnosed with NSCLC. All patients underwent limited brain MRI and routine workups. The control group comprised 131 patients with NSCLC who underwent limited brain MRI only if they had neurologic symptoms. The incidence of BM was 20.8% (38/183) in the study group and 4.6% (6/131) in the control group. The rate of upstaging based on the MRI data was 13.5% (15/111) overall and 15.9% (11/69) in patients that had been considered initially to be resectable surgically. There was no significant difference in survival outcome between the groups. Patients who had BM alone had a greater overall survival time (49 weeks) than those who had multiple systemic metastases (27 weeks; p=0.0307). In conclusions, limited brain MRI appears to be a useful, cost-effective method to screen for BM at the time of initial staging. And it may facilitate timely treatment of patients with NSCLC and improve their survival and quality of life.
Kim
Sun Young
SY
Department of Internal Medicine, College of Medicine, Cancer Research Institute, Chungnam National University, Daejon, Korea.
Kim
Jae Sung
JS
Park
Hee Sun
HS
Cho
Moon June
MJ
Kim
Ju Ock
JO
Kim
Jin Whan
JW
Song
Chang Jun
CJ
Lim
Seung Pyung
SP
Jung
Sung Soo
SS
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001932:Brain Neoplasms / Q000175:diagnosis* / Q000473:pathology / Q000556:secondary*; D002289:Carcinoma, Non-Small-Cell Lung / Q000175:diagnosis* / Q000473:pathology*; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000175:diagnosis* / Q000473:pathology; D008279:Magnetic Resonance Imaging / Q000191:economics* / Q000379:methods; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D011379:Prognosis; D013997:Time Factors
J Clin Oncol. 1999 Sep;17(9):2700-9
10561344
Chest. 1999 Mar;115(3):714-9
10084481
J Clin Oncol. 2001 Mar 1;19(5):1344-9
11230477
Cancer. 2001 Jun 15;91(12):2394-400
11413530
Lung Cancer. 2001 Dec;34 Suppl 3:S13-23
11740988
Lung Cancer. 2002 Jul;37(1):87-94
12057872
Cancer. 2002 Aug 1;95(3):605-12
12209754
Semin Oncol. 2003 Feb;30(1):38-46
12635088
Lung Cancer. 2003 Nov;42(2):189-93
14568686
Chest. 1984 Jun;85(6):774-6
6723388
Chest. 1984 Dec;86(6):850-3
6094117
J Clin Oncol. 1988 Sep;6(9):1474-80
3047337
AJNR Am J Neuroradiol. 1990 Jul-Aug;11(4):785-91
2114769
AJNR Am J Neuroradiol. 1991 Mar-Apr;12(2):293-300
1902031
Ann Thorac Surg. 1994 Apr;57(4):838-40
8166528
Am J Respir Crit Care Med. 1995 Jul;152(1):225-30
7599828
Ann Surg. 1995 Dec;222(6):700-10
8526576
Ann Thorac Surg. 1995 Dec;60(6):1563-70; discussion 1570-2
8787445
Ann Thorac Surg. 1996 Feb;61(2):546-50; discussion 551
8572765
J Clin Oncol. 1997 Feb;15(2):712-22
9053497
Int J Radiat Oncol Biol Phys. 1997 Mar 1;37(4):745-51
9128946
J Clin Oncol. 1998 Feb;16(2):622-34
9469351
Oncology. 2000 Nov;59(4):291-5
11096340